Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $181

Revolution Medicines

Revolution Medicines

RVMD

0.00

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ: RVMD) with a Outperform and raises the price target from $165 to $181.